| 0.348 -0.05 (-12.56%) | 08-20 13:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.63 | 1-year : | 0.85 |
| Resists | First : | 0.54 | Second : | 0.73 |
| Pivot price | 0.45  |
|||
| Supports | First : | 0.25 | Second : | 0.2 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.47 |
| MA(100) : | 0.7 |
MA(250) : | 0.89 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.5  |
D(3) : | 19.7 |
| RSI | RSI(14): 22.8 |
|||
| 52-week | High : | 1.98 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NRSN ] has closed below the lower bollinger band by 1.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 9.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.5 | 0.5 - 0.51 |
| Low: | 0.25 - 0.25 | 0.25 - 0.25 |
| Close: | 0.39 - 0.4 | 0.4 - 0.4 |
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Fri, 14 Aug 2026
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
Fri, 14 Aug 2026
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Thu, 13 Aug 2026
NeuroSense Issues CEO Letter to Shareholders - PR Newswire
Thu, 06 Aug 2026
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - PR Newswire
Thu, 06 Aug 2026
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
Mon, 03 Aug 2026
NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 2.334e+007 (%) |
| Held by Institutions | 25.6 (%) |
| Shares Short | 492 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.107e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -247.4 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 109.36 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.47 |
| Dividend | 0 |
| Forward Dividend | 547540 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|